Adjuvant Therapy for Renal Cell Carcinoma

December 5, 2013
Sumanta Kumar Pal, MD

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses adjuvant therapy for renal cell carcinoma (RCC).

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses adjuvant therapy for renal cell carcinoma (RCC).

Clinical Pearls:

  • Adjuvant therapy is not currently a standard of care for localized RCC, however there are several studies that could put these agents into that disease space
  • These studies are looking at VEGF- and mTOR-directed therapies
  • Results of the ASSURE trial, which compared sunitinib, sorafenib and placebo in the adjuvant setting, will hopefully report out within the next 2-3 years
  • Patients in the adjuvant setting may not tolerate the same doses as in the metastatic setting
  • The EVEREST trial, which compares everolimus to placebo in the adjuvant setting, is about halfway accrued.
  • Girentuximab, which targets CA9, was found to not have a significant impact on disease-free survival or overall survival